Volume 1, Issue 4, Pages (April 2012)

Slides:



Advertisements
Similar presentations
Figure S1 A B Figure S1. SPATA2 is required for TNFα or zVAD.fmk induced necroptosis in L929 cells. (A) L929 cells were transfected with a pool of four.
Advertisements

Volume 13, Issue 5, Pages (November 2015)
Matrix Metalloproteinase-9 Is Required for Tumor Vasculogenesis but Not for Angiogenesis: Role of Bone Marrow-Derived Myelomonocytic Cells  G-One Ahn,
Suppression of B-cell lymphomagenesis by the BH3-only proteins Bmf and Bad by Anna Frenzel, Verena Labi, Waldemar Chmelewskij, Christian Ploner, Stephan.
by Ji-Long Chen, Andre Limnander, and Paul B. Rothman
Sarah A. Best, Amy N. Nwaobasi, Chrysalyne D. Schmults, Matthew R
Induction of heme oxygenase-1 before conditioning results in improved survival and reduced graft-versus-host disease after experimental allogeneic bone.
Volume 44, Issue 1, Pages (January 2016)
Sarah A. Best, Amy N. Nwaobasi, Chrysalyne D. Schmults, Matthew R
The Requirement for Cyclin D Function in Tumor Maintenance
Volume 13, Issue 6, Pages (November 2015)
Volume 25, Issue 4, Pages (April 2014)
Short Telomeres Limit Tumor Progression In Vivo by Inducing Senescence
Volume 6, Issue 5, Pages (November 2009)
Haploinsufficiency of the ESCRT Component HD-PTP Predisposes to Cancer
DNA Damage-Mediated Induction of a Chemoresistant Niche
Volume 6, Issue 1, Pages (January 2014)
Preventing Allograft Rejection by Targeting Immune Metabolism
by Xue Li, Jared Sipple, Qishen Pang, and Wei Du
Volume 43, Issue 4, Pages (August 2011)
Volume 138, Issue 5, Pages e2 (May 2010)
Volume 23, Issue 3, Pages (March 2013)
Blocking Activator Protein 1 Activity in Donor Cells Reduces Severity of Acute Graft- Versus-Host Disease through Reciprocal Regulation of IL-17–Producing.
Volume 17, Issue 3, Pages (March 2010)
Volume 130, Issue 4, Pages (August 2007)
Volume 24, Issue 3, Pages (March 2006)
Volume 13, Issue 7, Pages (November 2015)
DNA Damage-Mediated Induction of a Chemoresistant Niche
Inhibition of KLF4 by Statins Reverses Adriamycin-Induced Metastasis and Cancer Stemness in Osteosarcoma Cells  Yangling Li, Miao Xian, Bo Yang, Meidan.
Kenichi Miharada, Valgardur Sigurdsson, Stefan Karlsson  Cell Reports 
Modeling the Therapeutic Efficacy of p53 Restoration in Tumors
Volume 29, Issue 3, Pages (May 2014)
Volume 14, Issue 8, Pages (March 2016)
Volume 19, Issue 6, Pages (June 2011)
Saskia Hemmers, Alexander Y. Rudensky  Cell Reports 
Matrix Metalloproteinase-9 Is Required for Tumor Vasculogenesis but Not for Angiogenesis: Role of Bone Marrow-Derived Myelomonocytic Cells  G-One Ahn,
Molecular Therapy - Nucleic Acids
Volume 6, Issue 1, Pages (January 2014)
Volume 7, Issue 5, Pages (May 2005)
Volume 25, Issue 7, Pages (July 2017)
Volume 28, Issue 4, Pages (April 2008)
Volume 11, Issue 3, Pages (September 2012)
CD25 expression distinguishes functionally distinct alloreactive CD4+ CD134+ (OX40+) T-cell subsets in acute graft-versus-host disease  Philip R Streeter,
Volume 38, Issue 3, Pages (March 2013)
Volume 38, Issue 3, Pages (March 2013)
Volume 50, Issue 2, Pages (April 2013)
Volume 8, Issue 6, Pages (September 2014)
Volume 26, Issue 6, Pages (June 2007)
Opposing Effects of TGF-β and IL-15 Cytokines Control the Number of Short-Lived Effector CD8+ T Cells  Shomyseh Sanjabi, Munir M. Mosaheb, Richard A.
Volume 31, Issue 1, Pages (July 2008)
Volume 25, Issue 4, Pages (April 2014)
CD4+ Lymphoid Tissue-Inducer Cells Promote Innate Immunity in the Gut
Haploinsufficiency at the Nkx3.1 locus
Volume 2, Issue 1, Pages (January 2008)
Volume 8, Issue 1, Pages (January 2011)
E3 Ubiquitin Ligase VHL Regulates Hypoxia-Inducible Factor-1α to Maintain Regulatory T Cell Stability and Suppressive Capacity  Jee H. Lee, Chris Elly,
Volume 12, Issue 4, Pages (July 2015)
Javed Mohammed, Andrew Ryscavage, Rolando Perez-Lorenzo, Andrew J
A Function of Fas-Associated Death Domain Protein in Cell Cycle Progression Localized to a Single Amino Acid at Its C-Terminal Region  Zi Chun Hua, Sue.
Volume 14, Issue 10, Pages (March 2016)
SOCS1 Prevents Potentially Skin-Reactive Cytotoxic T Lymphocytes from Gaining the Ability to Cause Inflammatory Lesions  Galaxia Maria Rodriguez, Dante.
Notch 1 Signaling Regulates Peripheral T Cell Activation
Volume 13, Issue 6, Pages (November 2015)
Cellular Heterogeneity in the Mouse Esophagus Implicates the Presence of a Nonquiescent Epithelial Stem Cell Population  Aaron D. DeWard, Julie Cramer,
Volume 13, Issue 5, Pages (November 2015)
Volume 9, Issue 5, Pages (November 1998)
Volume 10, Issue 8, Pages (March 2015)
Volume 7, Issue 6, Pages (June 2014)
Endogenous Control of Immunity against Infection: Tenascin-C Regulates TLR4- Mediated Inflammation via MicroRNA-155  Anna M. Piccinini, Kim S. Midwood 
Volume 2, Issue 6, Pages (December 2012)
Presentation transcript:

Volume 1, Issue 4, Pages 325-333 (April 2012) Targeting Synthetic Lethal Interactions between Myc and the eIF4F Complex Impedes Tumorigenesis  Chen-Ju Lin, Zeina Nasr, Prem K. Premsrirut, John A. Porco, Yoshitaka Hippo, Scott W. Lowe, Jerry Pelletier  Cell Reports  Volume 1, Issue 4, Pages 325-333 (April 2012) DOI: 10.1016/j.celrep.2012.02.010 Copyright © 2012 The Authors Terms and Conditions

Cell Reports 2012 1, 325-333DOI: (10.1016/j.celrep.2012.02.010) Copyright © 2012 The Authors Terms and Conditions

Figure 1 Transient Suppression of eIF4E Delays Myc-Dependent Tumor Initiation (A) Kaplan-Meier plot illustrating tumor-free survival of recipient C57BL/6 mice transplanted with 20 Eμ-Myc lymphoma cells or 2 × 106 bone marrow cells from 4-, 5-, and 6-week-old Eμ-Myc mice. (B) Forward light scatter from a flow cytometer of B220+ splenocytes from 6-week-old C57BL/6 and Eμ-Myc mice. This assay was used as an independent validation to confirm the prelymphomatous nature of Eμ-Myc cells used in the transplantation experiments in (A). (C) Western blot analysis of c-Myc transcriptional targets (eIF4E, eIF4AI, eIF4GI) in C57BL/6 (WT) and Eμ-Myc HSCs, B220+sIgM− pre-B cells, and splenocytes from mice of the indicated ages. (D) Suppression of eIF4E expression in B220+ cells isolated from 6-week-old mice of the indicated genotype pretreated with vehicle or DOX for 2 weeks. (E) Kaplan-Meier plot showing lymphoma-free survival of 4E.389/rtTA/Eμ-Myc (n = 12), 4E.610/rtTA/Eμ-Myc (n = 10), and FLuc.1309/rtTA/Eμ-Myc (n = 14) mice that had been treated with vehicle (red) or with DOX (black) for 21 days starting at 4 weeks of age. See also Figure S1. Cell Reports 2012 1, 325-333DOI: (10.1016/j.celrep.2012.02.010) Copyright © 2012 The Authors Terms and Conditions

Figure 2 Inducible Suppression of eIF4E Reduces the B220+ B Cell Compartment, Impairs Cell Division, and Augments Apoptosis in Premalignant B Cells (A) Flow cytometry analysis of B220+ B cells isolated from 6-week-old transgenic mice that had been treated with vehicle or DOX for 2 weeks. Error bars denote SEM (n = 3). ∗p < 0.002, as determined by the Student's t test. (B) Representative photographs of spleens and average spleen mass of indicated 6-week-old triple-transgenic mice that had been treated with vehicle or DOX for 2 weeks. Red dotted lines represent the range of spleen masses from four 6-week-old control C57BL/6 mice. Error bars denote SEM (n = 4). ∗p < 0.001, ∗∗p < 0.01. (C) Flow cytometry analysis of spleen cells isolated from 4E.389/rtTA/Eμ-Myc mice and stained for the indicated cell surface markers. Each marker positive population was also >90% GFP+. Error bars are SEM (n = 3). (D) Cell-cycle distribution of B220+ splenic B cells of the indicated genotype and DOX-treatment cohorts. Results are expressed as the average of three independent experiments (n = 3). ∗p < 0.01; ∗∗p < 0.05 for percent (%) G1 and S phase cells. (E) In situ TUNEL analysis on freshly isolated splenic cells from 5 week transgenic mice that had been treated with vehicle or DOX for 6 days. Error bars denote SEM (n = 3). ∗p < 0.05. See also Figure S2. Cell Reports 2012 1, 325-333DOI: (10.1016/j.celrep.2012.02.010) Copyright © 2012 The Authors Terms and Conditions

Figure 3 Inducible Suppression of eIF4E Impairs eIF4F Levels, Selectively Blocks Protein Synthesis, and Affects Production of Cyclin D1, Mcl-1, and Myc (A) Relative abundance of the eIF4F complex in B220+ cells from mice of the indicated genotype. (B) Protein synthesis rates in B220+ cells assessed by [35S]methionine incorporation and TCA precipitation. Error bars denote SEM (n = 3). (C) Western blot analysis of eIF4E-responsive targets in B220+ cells isolated from 6-week-old mice. Cells were isolated from 4E.389/rtTA (lane 1), 4E.389/rtTA/Eμ-Myc (lane 2), and four independent C57BL/6 (lanes 3–6) or Eμ-Myc (lanes 7–10) mice. (D) Western blot analysis showing reductions in Mcl-1, Cyclin D1, and Myc levels upon suppression of eIF4E in B220+ cells in vivo. (E) qRT-PCR quantitation of the indicated mRNA levels from B220+ splenocytes (n = 6; ∗p = 0.003). (F) Western blot analysis indicating levels of eIF4E targets upon eIF4E suppression in B220+ cells. See also Figure S3. Cell Reports 2012 1, 325-333DOI: (10.1016/j.celrep.2012.02.010) Copyright © 2012 The Authors Terms and Conditions

Figure 4 Blocking Eμ-Myc-Driven Tumor Initiation by Pharmacological Suppression of eIF4F Activity (A) Kaplan-Meier plot showing lymphoma-free survival of 4-week-old Eμ-Myc mice treated with or without 0.2 mg/kg silvestrol (n = 7; p < 0.01) for 23 days. (B) Percent B220+ cells isolated from 6-week-old C57BL/6 or Eμ-Myc mice that had been treated with vehicle or silvestrol for 2 weeks. Error bar represent SEM (n = 3). ∗p < 0.01. (C) Percent CD4+ and CD11b+ cells isolated from 6-week-old C57BL/6 or Eμ-Myc mice that had been treated with vehicle or silvestrol for 2 weeks. Error bar represent SEM (n = 3). ∗p < 0.001. (D) Cell-cycle distribution of B220+ splenic B cells of the indicated genotype and drug treatments. Results are expressed as the average of three independent experiments. (E) In situ TUNEL analysis on freshly isolated splenic cells from 5-week-old mice that had been treated with vehicle or silvestrol for 6 days (n = 3 mice). ∗p < 0.001. (F) Western blot analysis of eIF4F targets in splenic B220+ cells isolated from untreated or silvestrol-treated Eμ-Myc or C57BL/6 mice. (G) Sensitivity of NIH/3T3 cells to silvestrol. NIH/3T3 or Myc/ER NIH 3T3 cells were exposed to vehicle or 250 nM 4-OHT for 18 hr and then to silvestrol for an additional 24 hr at the indicated concentrations. Cell viability was determined using the Sulforhodamine B (SRB) colorimetric assay and is set relative to vehicle-treated cells. Values represent the average of three biological replicates, and error bars denote SEM. (H) Relationship among Myc, eIF4F, and eIF4E effectors leading to increased cell-cycle progression and survival advantage during the premalignant phase of lymphomagenesis. The plus (+) sign indicates that increased eIF4F levels also stimulate c-Myc mRNA translation (Lin et al., 2008). See also Figure S4. Cell Reports 2012 1, 325-333DOI: (10.1016/j.celrep.2012.02.010) Copyright © 2012 The Authors Terms and Conditions

Figure S1 Engineering Doxycycline-Inducible eIF4E shRNAs in the Col1AI Locus, Related to Figure 1 (A) Configuration of the Col1A1 allele in CTGM-targeted ES cells. (B) Suppression of eIF4E in CTGM targeted ES cells exposed to 1 μg/ml DOX for the indicated time and analyzed by Western blotting. (C) Immunohistochemical analysis of representative tissues from untreated and DOX-treated (14 days) 4E.389/rtTA mice probed with anti-EGFP or anti-eIF4E antibodies and counterstained with hematoxylin. Bar, represents 50 μm. In DOX-treated 4E.389/rtTA mice, eIF4E expression is suppressed in liver hepatocytes, red and white pulp of the spleen, skin keratinocytes and crypt cells and villi of the intestine. (D) Western blot of MEFs harvested from a 4E.389/rtTA embryo and treated ex vivo with 1 μg/ml DOX for 3 days. Cell Reports 2012 1, 325-333DOI: (10.1016/j.celrep.2012.02.010) Copyright © 2012 The Authors Terms and Conditions

Figure S2 Suppression of eIF4E Causes a Proliferative Disadvantage in MYC Overexpressing Cells, Related to Figure 2 (A) Flow cytometry analysis of bone marrow derived B220+ cells from 6 wk old transgenic mice that had been treated with vehicle or DOX for 2 wks. Error bars denote SEM; n=3. (B) Schematic diagram illustrating two-color FACs assay to assess the consequences of eIF4E depletion and Myc over-expression. In this setting, Myc expression is linked to GFP and shRNAmir expression is linked to turboRFP (tRFP). (C) Quantitation of flow cytometry analysis of %GFP+, %RFP+, and %GFP+RFP+ in NIH-3T3 and hTert-BJ cells two days post-infection with MSCV-GFP or MSCV-Myc-GFP and LMS-tRFP-shRNAmir harboring the indicated shRNA. n=3. Bars represent SEM. (D) Apoptosis in NIH 3T3 and hTert-BJ cells co-infected with MSCV or MSCV-Myc and MLS-shFLuc.1309, MLS-sh4E.389, or MLS-sh4E.610. Graph represents quantitation of flow cytometry analysis of % GFP+/PI+ cells. n=2, Bars represent SEM. Cell Reports 2012 1, 325-333DOI: (10.1016/j.celrep.2012.02.010) Copyright © 2012 The Authors Terms and Conditions

Figure S3 Selective Inhibition of Protein Synthesis upon eIF4E Suppression, Related to Figure 3 (A) SDS-PAGE analysis of 35S-labelled proteins from B220+ cells isolated from mice of the specified genotype. (B) Western blot analysis of eIF4E responsive targets in bone marrow-derived B220+ lymphocytes from vehicle or DOX-treated mice of the indicated genotypes. (C) Reversible suppression of eIF4E targets. Western blot analysis of whole cell lysates from 4E.389/rtTA/Eμ-Myc B220+ cells isolated from mice before (lanes 1, 4), during (lanes 2, 5), and after (lanes 3, 6) the indicated exposure to DOX. B220+ cells were isolated from spleens (lanes 1-3) or bone marrow (lanes 4-6). (D) Western blot showing that expression of the cap-independent p27Kip1 transcript is unaffected by suppression of eIF4E levels in vivo in B220+ cells. Cell Reports 2012 1, 325-333DOI: (10.1016/j.celrep.2012.02.010) Copyright © 2012 The Authors Terms and Conditions

Figure S4 Suppression of eIF4E in the Intestines Leads to a Degenerative Phenotype that Is Readily and Completely Reversible, Related to Figure 4 (A) Four wk old 4E.389/rtTA/Eμ-Myc or FLuc.1309/rtTA/Eμ-Myc mice were treated with DOX (starting at Day 0) for 2 wks and then taken off DOX (at Day 14). Body weights were monitored every 2 days. Values represent the average of three independent mice/experiment. Error bars are SEM. (B) Four wk old 4E.389/rtTA/Eμ-Myc mice were treated with or without DOX for 2 wks, and then were taken off DOX for 1 wk. Sections of small (left panels) and large (right panels) intestine were subjected to hematoxylin and TUNEL staining. Representative results are shown. There is multifocal crypt depletion (bottom 1/3 – 2/3) and the epithelium lining the crypts is hyperplastic and immature. The dotted arrows denote the goblet cells and the solid arrows show apoptotic cells. Bars, represent 25 μM. (C) Quantitation of apoptotic cells in intestines of vehicle and DOX-treated 4E.389/rtTA/Eμ-Myc mice. Apoptotic cells were quantitated on an Aperio ScanScope using the software ImageScope from 6 different fields. Error bars are SEM. Cell Reports 2012 1, 325-333DOI: (10.1016/j.celrep.2012.02.010) Copyright © 2012 The Authors Terms and Conditions